Praxis Precision Medicines (PRAX) FCF Margin (2023 - 2024)
Praxis Precision Medicines (PRAX) recorded quarterly FCF Margin of 752.0% in Q4 2024, up 91.74% quarter-over-quarter from 9105.96% in Q3 2024, and up 388120.0% on a YoY basis from N/an in Q1 2024.
Praxis Precision Medicines (PRAX) FCF Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' FCF Margin history runs 2 years deep, the most recent figure standing at 752.0% for Q4 2024.
- In Q4 2024, FCF Margin rose 388120.0% year-over-year to 752.0%; the TTM figure through Sep 2025 stood at 3067.41% (up 313172.0% YoY), while the FY2024 annual figure was 1540.48%, up 300329.0% from the prior year.
- FCF Margin was 752.0% for Q4 2024 at Praxis Precision Medicines, up from 9105.96% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 752.0% in Q4 2024 to a low of 9105.96% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Praxis Precision Medicines | 200.22 Mn | -586.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -752.00% |
| Sep 30, 2024 | -9,105.96% |
| Jun 30, 2024 | -7,640.90% |
| Mar 31, 2024 | -4,839.21% |
| Dec 31, 2023 | -4,633.20% |
| Sep 30, 2023 | -4,971.15% |
| Jun 30, 2023 | -3,996.67% |
| Mar 31, 2023 | -4,809.08% |